BRPI0517954A - forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica - Google Patents

forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica

Info

Publication number
BRPI0517954A
BRPI0517954A BRPI0517954-8A BRPI0517954A BRPI0517954A BR PI0517954 A BRPI0517954 A BR PI0517954A BR PI0517954 A BRPI0517954 A BR PI0517954A BR PI0517954 A BRPI0517954 A BR PI0517954A
Authority
BR
Brazil
Prior art keywords
dosage form
pharmaceutical dosage
oral pharmaceutical
preparing
ppi
Prior art date
Application number
BRPI0517954-8A
Other languages
English (en)
Inventor
Niclas Clemmensen
Jan-Erik L Froth
Henrik Sahlen
Katrin Walter
Peter Wang
Martin Wikberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0517954A publication Critical patent/BRPI0517954A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMA DE DOSAGEM FARMACêUTICA SóLIDA ORAL, PROCESSO PARA A PREPARAçãO DE UMA FORMA DE DOSAGEM FARMACêUTICA ORAL, MéTODO PARA APERFEIçOAR A INIBIçãO DE SECREçãO DE áCIDO GáSTRICO, E, USO DE UMA FORMA DE DOSAGEM FARMACêUTICA. Uma forma de dosagem farmacêutica sólida oral, que compreende um inibidor de bomba de próton (PPI) sensível a ácido como uma droga ativa única, que libera o PPI em dois pulsos separados, um imediato e um retardado. O PPI é formulado como um material de núcleo, sob a forma de comprimidos, que são revestidos, entre outros, com uma combinação de uma camada de modificação de liberação retardada e uma camada de controle de tempo de atraso, que juntas alcançam propriedades de liberação benéficas. Os comprimidos são ainda providos com uma camada de revestimento entérico. A aplicação também se refere a processos para a preparação das formas de dosagem, assim como a seu uso no tratamento de doenças gastrintestinais.
BRPI0517954-8A 2004-11-04 2005-11-02 forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica BRPI0517954A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62564904P 2004-11-04 2004-11-04
PCT/SE2005/001643 WO2006049565A1 (en) 2004-11-04 2005-11-02 New modified release tablet formulations for proton pump inhibitors

Publications (1)

Publication Number Publication Date
BRPI0517954A true BRPI0517954A (pt) 2008-10-21

Family

ID=36319458

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517954-8A BRPI0517954A (pt) 2004-11-04 2005-11-02 forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica

Country Status (17)

Country Link
US (1) US20080003281A1 (pt)
EP (1) EP1809262A4 (pt)
JP (1) JP2008519070A (pt)
KR (1) KR20070083956A (pt)
CN (1) CN101094661A (pt)
AR (1) AR052225A1 (pt)
AU (1) AU2005301369A1 (pt)
BR (1) BRPI0517954A (pt)
CA (1) CA2584419A1 (pt)
IL (1) IL182686A0 (pt)
MX (1) MX2007004987A (pt)
NO (1) NO20072257L (pt)
RU (1) RU2007115544A (pt)
TW (1) TW200624126A (pt)
UY (1) UY29193A1 (pt)
WO (1) WO2006049565A1 (pt)
ZA (1) ZA200703111B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
AU2008282900B2 (en) * 2007-07-27 2014-05-22 Depomed, Inc. Pulsatile gastric retentive dosage forms
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US10485770B2 (en) * 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384747A3 (en) * 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
US8563035B2 (en) 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
EP2670387A1 (en) * 2011-02-03 2013-12-11 Lupin Limited Oral controlled release pharmaceutical compositions of bepotastine
WO2012111024A1 (en) * 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104856971B (zh) * 2015-05-15 2019-05-14 暨南大学 一种脉冲双释放制剂及其制备方法与应用
CN105012274A (zh) * 2015-06-27 2015-11-04 上海信谊万象药业股份有限公司 一种奥美拉唑微片胶囊制剂及其制备方法
CN104940170A (zh) * 2015-07-23 2015-09-30 浙江亚太药业股份有限公司 一种埃索美拉唑镁肠溶胶囊及其制备方法
EP3393469A4 (en) * 2015-12-22 2019-09-25 Harrow Health, Inc. PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KIDNEY STONES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101877350B1 (ko) 2016-10-28 2018-08-09 한미약품 주식회사 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
JP6336651B1 (ja) * 2016-12-15 2018-06-06 大原薬品工業株式会社 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
WO2019030610A1 (en) * 2017-08-11 2019-02-14 Solutions In Innovative Research Pvt. Ltd. PHARMACEUTICAL COMPOSITIONS WITH DUAL DIRECTLY COMPRESSIBLE MEDICAMENT RELEASE
BR112022014430A2 (pt) * 2020-01-23 2022-09-13 Hanmi Pharm Ind Co Ltd Formulação farmacêutica composta

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
WO1998019668A1 (en) * 1996-11-06 1998-05-14 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EP1074249A1 (en) * 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
JP2003171277A (ja) * 2001-12-07 2003-06-17 Wyeth Lederle Japan Ltd 薬物放出時間制御型固形製剤
CA2496044A1 (en) * 2002-08-16 2004-02-26 Themis Laboratories Private Limited A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
EP1742630A4 (en) * 2004-04-16 2010-01-20 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND PROKINETIC AGENT

Also Published As

Publication number Publication date
EP1809262A1 (en) 2007-07-25
KR20070083956A (ko) 2007-08-24
ZA200703111B (en) 2009-09-30
TW200624126A (en) 2006-07-16
JP2008519070A (ja) 2008-06-05
EP1809262A4 (en) 2012-09-05
IL182686A0 (en) 2007-09-20
AR052225A1 (es) 2007-03-07
RU2007115544A (ru) 2008-12-10
US20080003281A1 (en) 2008-01-03
NO20072257L (no) 2007-08-03
UY29193A1 (es) 2006-06-30
MX2007004987A (es) 2007-06-14
CN101094661A (zh) 2007-12-26
WO2006049565A1 (en) 2006-05-11
CA2584419A1 (en) 2006-05-11
AU2005301369A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0517954A (pt) forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0517933A (pt) forma de dosagem farmacêutica sólida oral, processo para a preparação de uma forma de dosagem farmacêutica oral, método para aperfeiçoar a inibição de secreção de ácido gástrico, e, uso de uma forma de dosagem farmacêutica
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
BRPI1007945C1 (pt) composição farmacêutica, comprimido, e, usos de nitazoxanida ou de um seu análogo
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
EA200970267A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ МНОЖЕСТВО МИНИ-ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР ФАКТОРА Xa
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
PE20110943A1 (es) Formulacion oral solida de alisquireno
WO2009043926A3 (en) Oral fast disintegrating tablets
WO2008000731A3 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
Lee et al. Effect of Peroxisome Proliferator—Activated Receptor Gamma Agonists on Myofibroblast Differentiation and Collagen Production in Nasal Polyp—Derived Fibroblasts
WO2012161622A3 (ru) Стимуляторы секреции инкретиновых гормонов, способ их получения и применения
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
DOP2011000267A (es) Composicion farmaceutica oral para uso en enfermedades respiratorias
Ding et al. Panax notoginseng saponins protect against chronic ethanol-induced hepatic steatosis
ECSP099649A (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor
RU2006126461A (ru) Способ наружного лечения грибковых заболеваний ногтевых пластинок стоп

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]